RPG Life Sciences (NSE:RPGLIFE) ROCE %: 25.67% (As of Mar. 2026)


NSE:RPGLIFE RPG Life Sciences Ltd NSE:RPGLIFE
92 GF Score
Price ₹2,276.40
GF Value ₹2,359.83
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is RPG Life Sciences ROCE %?

RPG Life Sciences NSE:RPGLIFE -0.54% 92 ROCE % is 25.67% as of Mar. 2026. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 92/100 and a GF Value™ of ₹2,359.83 (Fairly Valued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. RPG Life Sciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 25.67%.

RPG Life Sciences  (NSE:RPGLIFE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

RPG Life Sciences ROCE % Related Terms

RPG Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for RPG Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RPG Life Sciences ROCE % Chart

RPG Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.19 31.66 33.87 50.77 26.50

RPG Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.43 26.44 35.28 20.90 25.67
NSE:RPGLIFE
92GF Score
RPG Life Sciences Ltd NSE:RPGLIFE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RPG Life Sciences ROCE % Calculation

RPG Life Sciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=1550.9/( ( (6578.1 - 1198.3) + (7931.6 - 1605.7) )/ 2 )
=1550.9/( (5379.8+6325.9)/ 2 )
=1550.9/5852.85
=26.50 %

RPG Life Sciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1623.6/( ( (0 - 0) + (7931.6 - 1605.7) )/ 1 )
=1623.6/( ( 0 + 6325.9 )/ 1 )
=1623.6/6325.9
=25.67 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 25.67% mean?
RPG Life Sciences (NSE:RPGLIFE) has a ROCE % of 25.67% as of Mar. 2026.
Is RPG Life Sciences' ROCE % too high?
RPG Life Sciences' current ROCE % is 25.67%. The Drug Manufacturers industry median ROCE % is 7.01. RPG Life Sciences' value of 25.67% is 266.2% above this industry median. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' ROCE % compare to ZTS?
RPG Life Sciences' ROCE % of 25.67% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. RPG Life Sciences' value of 25.67% is 266.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current ROCE % of 25.67% is 266.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current ROCE % is 25.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,359.83, compared to a current price of ₹2,276.40 — trading 3.5% below its estimated fair value. The current ROCE % is 25.67% and 266.2% above the Drug Manufacturers industry median of 7.01. RPG Life Sciences' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current ROCE % is 25.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, RPG Life Sciences stock appears to be undervalued. The current stock price of ₹2,276.40 is trading 3.5% below its estimated GF Value™ of ₹2,359.83. GuruFocus considers RPG Life Sciences to be Fairly Valued.

Key valuation signals for NSE:RPGLIFE:

  • ROCE %: 25.67%
  • GF Value™: ₹2,359.83 vs. price of ₹2,276.40 (3.5% below fair value)
  • GF Score™: 92/100 with 3 warning signs
  • Industry Position: 266.2% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RPG Life Sciences Business Description

Other Exchanges 532983:India
Address 463, Dr. Annie Besant Road, RPG House, Near Old Passport Office, Worli, Mumbai, MH, IND, 400030
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score

Get the complete analysis for NSE:RPGLIFE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,276.40
Price
₹2,359.83
GF Value